SCYNEXIS INC
SCYX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SCYX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SCYX
SCYNEXIS INC is a biopharmaceutical company focused on developing and commercializing antifungal therapies, including its approved product BREXAFEMME, and advancing a pipeline of AMP kinase activator programs and other candidates such as SCY-770 and SCY-247.
Key risk: Capital insufficiency
BioSniper Score
Based on 6 of 6 signals
Market Cap
$53.6M
Cash Runway
10.6 moLead Asset
brexafemme (Approved)
Next Catalyst
Phase2_Topline · Dec 31, 2027Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 7 clinical trials · 2 catalysts for SCYNEXIS INC.
SCYNEXIS INC is a biopharmaceutical company focused on developing and commercializing antifungal therapies, including its approved product BREXAFEMME, and advancing a pipeline of AMP kinase activator programs and other candidates such as SCY-770 and SCY-247.
- SCYNEXIS has an approved antifungal product, BREXAFEMME, and is developing pipeline candidates SCY-770 and SCY-247 [sec_mda · as of 2026-08-10].
- As of June 30, 2026, the company reported cash and equivalents of $10.7 million, total revenue of $0.2 million, and net income of $7.4 million [sec].
- The company anticipates needing substantial additional funding to continue operations and development activities [sec_mda · as of 2026-08-10].
- SCYNEXIS is advancing an AMP kinase activator program acquired through an asset purchase agreement [sec · filed 2026-03-31].
- The company faces risks related to clinical development, regulatory approvals, and capital requirements [sec_mda · as of 2026-08-10].
What works
- SCYNEXIS has an approved product, BREXAFEMME, providing a commercial foothold in the antifungal market [sec_mda · as of 2026-08-10].
- The company is advancing a novel AMP kinase activator program, which may offer a new therapeutic approach [sec · filed 2026-03-31].
- SCYNEXIS has a pipeline of clinical candidates (SCY-770, SCY-247) targeting antifungal indications [sec_mda · as of 2026-08-10].
What to weigh
- SCYNEXIS has limited cash reserves ($10.7 million as of June 30, 2026) and will require substantial additional capital to fund operations and development [sec] [sec_mda · as of 2026-08-10].
- The company's ability to continue as a going concern is dependent on raising additional funds, which may not be available on favorable terms [sec · filed 2022-05-12].
- Clinical development of SCY-770 and SCY-247 is subject to significant risks, including potential delays, regulatory hurdles, and high costs [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
SCYNEXIS will need substantial additional funding for its operations and development programs.
“We anticipate that we will need substantial additional funding in connection with our continuing future operations.”
SEC filings · August 10, 2026
The company's cash position as of March 31, 2022 was $95.2 million, but it has since decreased significantly.
“These capital resources primarily comprised cash and cash equivalents of $ 95.2 million at March 31, 2022.”
SEC filings · May 12, 2022
SCYNEXIS is developing SCY-770 and SCY-247 as part of its pipeline.
“the progress, and costs, of the clinical development of SCY-770 and SCY-247;”
SEC MD&A · August 10, 2026
The company has an AMP kinase activator program acquired via an asset purchase agreement.
“potential commercial opportunity for products containing acquired compounds, and the Company's plans for research, development and commercialization of the AMP kinase activator program.”
SEC filings · March 31, 2026
Catalyst timeline
- 2027-12-31 · Phase2_Topline · scy-770 — Phase 2 Readout: scy-770 — Topline data from the Phase 2 trial of SCY-770 will provide initial efficacy and safety signals for this antifungal candidate.
- 2039-06-10 · Patent_Expiry · BREXAFEMME — Patent/Exclusivity Expiry: BREXAFEMME — The patent or exclusivity protection for BREXAFEMME expires, potentially allowing generic competition.
Risks & what to watch (4)›
Key risks
- Capital insufficiency — SCYNEXIS has limited cash ($10.7M as of June 30, 2026) and requires substantial additional funding to continue operations [sec] [sec_mda · as of 2026-08-10].
- Clinical development risk — Pipeline candidates SCY-770 and SCY-247 face risks of failure, delays, and high costs in clinical trials [sec_mda · as of 2026-08-10].
- Regulatory approval risk — The outcome, costs, and timing of FDA and other regulatory approvals are uncertain for pipeline candidates [sec_mda · as of 2026-08-10].
- Dependence on partnerships — The company's liquidity could be affected by its ability to secure strategic alliances or licensing arrangements [sec · filed 2022-05-12].
What to watch
- Phase 2 topline data for SCY-770 expected by the end of 2027 [catalyst].
- Patent/exclusivity expiry for BREXAFEMME in June 2039, which may affect future revenue [catalyst].
- SCYNEXIS's ability to raise additional capital to fund operations beyond its current cash runway [sec_mda · as of 2026-08-10].
- Progress in clinical development of SCY-247 and the AMP kinase activator program [sec_mda · as of 2026-08-10].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run SCYNEXIS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SCYNEXIS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
10.6 months
D/E 0.12 · 0% dilution
Lead: Approved
2 candidates
2 upcoming, next in ~488d
1 buy · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
42
Total value held
$21.3M
| Holder | Shares | Value |
|---|---|---|
| great point partners llc | 7,554,347 | $6.9M |
| avidity partners management lp | 4,163,320 | $3.8M |
| vanguard capital management llc | 3,128,796 | $2.9M |
| heights capital management, inc | 2,086,960 | $1.9M |
| kingdon capital management, l.l.c. | 1,982,491 | $1.8M |
| dafna capital management llc | 1,086,956 | $997K |
| millennium management llc | 622,161 | $570K |
| geode capital management, llc | 486,368 | $446K |
| blackrock, inc. | 332,194 | $305K |
| vanguard fiduciary trust co | 225,736 | $207K |
Showing top 10 of 42 institutional holders of SCYNEXIS INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 3.2%
- Days to cover
- 1.4
- Shares short
- 1,169,538
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SCYX short interestGovernance
Frequently asked questions
What is the AI investment thesis for SCYNEXIS INC?
SCYNEXIS INC is a biopharmaceutical company focused on developing and commercializing antifungal therapies, including its approved product BREXAFEMME, and advancing a pipeline of AMP kinase activator programs and other candidates such as SCY-770 and SCY-247.
What is SCYNEXIS INC's lead drug candidate?
SCYNEXIS INC's most advanced tracked candidate is brexafemme (Approved) for vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).
What is SCYNEXIS INC's next catalyst?
SCYNEXIS INC's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: scy-770" — expected December 31, 2027.
Who is the CEO of SCYNEXIS INC?
Dr. David Gonzalez Angulo M.D. is the chief executive officer of SCYNEXIS INC (SCYX).
Where is SCYNEXIS INC headquartered?
SCYNEXIS INC (SCYX) is headquartered in Jersey City, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.